Affinage

CBX7

Chromobox protein homolog 7 · UniProt O95931

Length
251 aa
Mass
28.3 kDa
Annotated
2026-06-09
100 papers in source corpus 37 papers cited in narrative 36 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 10/10 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CBX7 is a chromodomain subunit of Polycomb repressive complex 1 (PRC1) that reads repressive chromatin marks and directs transcriptional silencing of cell-cycle and tumor-suppressor loci, most prominently the INK4a/ARF locus, to control cellular senescence and proliferative lifespan (PMID:14647293, PMID:15897876, PMID:22214847). Chromatin targeting requires bivalent recognition: the chromodomain engages H3K27me3 — and preferentially Ser31-phosphorylated H3.3K27me3 nucleosomes — while a chromodomain–AT-hook-like (ATL) unit co-recognizes DNA, with both inputs needed for stable target binding in living cells (PMID:27723458, PMID:41582043). The same chromodomain binds noncoding RNA, including ANRIL, and this RNA interaction acts in concert with H3K27me3 reading to enforce repression of INK4b/ARF/INK4a, while transcriptome-wide CLIP shows CBX7 footprints concentrated in mRNA 3' UTRs through defined sequence motifs (PMID:20541999, PMID:29073373). Once recruited, CBX7 is required for Ring1B deposition on chromatin in embryonic stem cells, where it is the dominant PRC1 ortholog directing early-lineage commitment and repressing other Cbx paralogs (PMID:23273917, PMID:22226354). CBX7 nucleates layered silencing by recruiting co-repressors: HDAC2 at the CCNE1 promoter (PMID:22214847), DNA methyltransferases at target promoters (PMID:19602592, PMID:35693076), and H3K9 methyltransferases SUV39H2, EHMT1/2 and SETDB1 to seed H3K9 methylation, the latter recognized through trimethyl-lysine motifs resembling H3K27me3 (PMID:21060834, PMID:30759399, PMID:39613290). Through these activities CBX7 represses a broad set of oncogenic effectors — CCNE1, AKR1B10, PDE4B, FGFR3, USP44, SPP1 and the Twist1-dependent EphA2 program — thereby restraining ERK, PI3K-AKT, c-MYC/glycolysis and metastatic transcriptional outputs (PMID:22214847, PMID:34035231, PMID:34977026, PMID:36396821, PMID:37791390, PMID:32205869), while in some contexts acting as a transcriptional activator, cooperating with p300 to induce the Wnt antagonist DKK-1 and activating FOS/FOSB/EGR1 (PMID:25351982, PMID:24865347). CBX7 activity is itself controlled post-translationally: MAPK signaling phosphorylates Thr-118 near the Polycomb box to strengthen PRC1 association, and the E3 ligases RNF26 and RNF2 drive its ubiquitin-mediated proteasomal degradation (PMID:24194518, PMID:35342353, PMID:39456039). Distinct isoforms partition between nucleus and cytoplasm with opposing effects on proliferation, and beyond its canonical repressive role CBX7 functions in lymphoid cells as a cytosolic signaling scaffold for c-Raf/MEK1/2/CK2-α to sustain ERK1/2 activity and as a methylation-dependent transcriptional activator of cytokine genes (PMID:32415167, PMID:41686891). CBX7 also drives a developmental cell-cycle exit program through a TARDBP/RBM38 axis that limits cardiomyocyte proliferation (PMID:37158107). The chromodomain methyl-lysine cage is a validated small-molecule target whose inhibition or allosteric re-equilibration displaces CBX7 from target loci and derepresses p16/CDKN2A (PMID:25660273, PMID:27326334, PMID:31422906).

Mechanistic history

Synthesis pass · year-by-year structured walk · 36 steps
  1. 2003 High

    Established CBX7 as a functional PRC1 component whose repression of the Ink4a/Arf locus sets cellular proliferative lifespan, defining its core biology.

    Evidence Co-IP with Ring1, Polycomb-body immunofluorescence, and shRNA knockdown with p16/Arf readout in a senescence-bypass cDNA screen

    PMID:14647293

    Open questions at the time
    • Did not resolve how CBX7 selects the INK4a/ARF locus
    • Co-repressor machinery downstream of Ring1 not yet defined
  2. 2005 Medium

    Extended INK4a/ARF repression to human prostate cells and showed the growth phenotype depends on intact p16/Rb and p14ARF/p53 pathways.

    Evidence shRNA knockdown with Western blot and growth assays in LNCaP and PC-3 cells

    PMID:15897876

    Open questions at the time
    • Direct promoter occupancy not shown in this study
    • Limited to two cell lines from one lab
  3. 2007 High

    Placed CBX7 genetically upstream of the Arf-p53 axis in vivo, demonstrating oncogenic cooperation with c-Myc during lymphomagenesis.

    Evidence Lymphoid-targeted Cbx7 transgenic mice with genetic epistasis and tumor characterization

    PMID:17374722

    Open questions at the time
    • Molecular basis of c-Myc cooperation not defined
    • Targets beyond Ink4a/Arf in lymphoma not identified
  4. 2009 Medium

    Connected CBX7 to DNA methylation by showing it associates with DNMTs and can seed promoter hypermethylation, linking Polycomb repression to a heritable silencing layer.

    Evidence Co-IP and ChIP for DNMT assembly at CBX7 targets with gain/loss in embryonal carcinoma cells

    PMID:19602592

    Open questions at the time
    • Direct vs. indirect DNMT recruitment unresolved
    • Single lab, single cell context
  5. 2010 High

    Defined the chromodomain as a dual H3K27me3- and RNA-reader, showing ANRIL binding is required for INK4 locus repression and revealing the structural interplay between the two ligands.

    Evidence RNA-IP, NMR of chromodomain–RNA interaction, separation-of-function chromodomain mutants, ChIP and senescence assays

    PMID:20541999

    Open questions at the time
    • How RNA and H3K27me3 binding are coordinated kinetically not resolved
    • Generality beyond ANRIL not addressed here
  6. 2010 Medium

    Demonstrated CBX7 recruits the H3K9 methyltransferase SUV39H2 to seed H3K9me3, coupling Polycomb to H3K9 methylation in cis.

    Evidence ChIP for CBX7/SUV39H2/H3K9me3 at p16, BiFC, and chromodomain/Pc-box mutants with siRNA

    PMID:21060834

    Open questions at the time
    • Direct SUV39H2 contact surface not mapped
    • Restricted to the p16 locus
  7. 2012 High

    Showed CBX7 is required for Ring1B chromatin recruitment in ESCs and is the dominant PRC1 ortholog controlling early lineage commitment and Cbx paralog repression.

    Evidence ChIP-seq, Cbx7 knockdown with Ring1B recruitment readout, reporter and differentiation assays (two papers)

    PMID:22226354 PMID:23273917

    Open questions at the time
    • Mechanism distinguishing Cbx7- vs RYBP-PRC1 targeting not fully defined
    • Stoichiometry within PRC1 not measured
  8. 2012 High

    An in vivo knockout established CBX7 as a tumor suppressor and identified CCNE1 as a direct target repressed via an HDAC2-containing complex.

    Evidence Cbx7 KO mice with tumor phenotype, MEF senescence assays, ChIP for CBX7/HDAC2 at CCNE1, human tumor correlation

    PMID:22214847

    Open questions at the time
    • HDAC2 recruitment mechanism not defined
    • Full target set behind the KO phenotype unknown
  9. 2013 Medium

    Identified Thr-118 phosphorylation by MAPK signaling as a switch that strengthens CBX7–PRC1 association, linking upstream kinase signaling to Polycomb function.

    Evidence Mass spectrometry site mapping, phospho-specific antibody, MEK inhibitor and EGF stimulation with Co-IP, phosphomimetic p16 repression assay

    PMID:24194518

    Open questions at the time
    • Magnitude of functional effect modest
    • Responsible kinase not directly identified
  10. 2014 Medium

    Revealed a transcriptional-activator mode in which CBX7 cooperates with p300 to induce DKK-1 and restrain Wnt/β-catenin signaling and stem-like populations.

    Evidence ChIP for CBX7/p300 and acetylation at DKK-1, knockdown/overexpression, pharmacological DKK-1 inhibition rescue

    PMID:25351982

    Open questions at the time
    • How CBX7 switches between repressor and activator modes unknown
    • Single lab
  11. 2014 Medium

    Broadened the CBX7 regulon to include both repressed (SPP1) and activated (FOS/FOSB/EGR1) genes via direct promoter occupancy.

    Evidence Expression profiling after CBX7 restoration, ChIP at promoters, tissue correlation in thyroid and lung carcinoma

    PMID:24865347

    Open questions at the time
    • Determinants of activation vs repression at each promoter unresolved
  12. 2015 High

    Provided crystal structures of the chromodomain with inhibitors that compete with H3K27me3 and pharmacologically derepress p16, validating the methyl-lysine cage as a druggable target.

    Evidence X-ray crystallography, fluorescence polarization, ChIP displacement and expression in PC3 cells (MS37452)

    PMID:25660273

    Open questions at the time
    • Inhibitor selectivity across CBX paralogs not fully resolved
  13. 2016 High

    Live-cell single-molecule tracking showed CBX7 requires combinatorial H3K27me3 and DNA co-recognition via a chromodomain–ATL unit for chromatin targeting.

    Evidence Single-molecule tracking, CRISPR disruption of the H3K27me3 pathway, biochemical DNA-binding assays, CD/ATL mutants

    PMID:27723458

    Open questions at the time
    • Sequence specificity of the DNA-binding unit not defined
    • Interplay with RNA binding during targeting unresolved
  14. 2016 High

    Discovered a Class B antagonist (MS351) that selectively blocks H3K27me3 binding when the chromodomain is RNA-bound, dissecting the RNA-versus-histone reading states pharmacologically.

    Evidence Crystal structure of CBX7ChD/MS351, fluorescence polarization, p16 derepression in mESC and PC3

    PMID:27326334

    Open questions at the time
    • In vivo efficacy not established
    • Selectivity profile limited
  15. 2017 High

    Transcriptome-wide CLIP defined CBX7 as an mRNA 3' UTR binder with discrete sequence motifs, expanding its RNA interactome beyond ANRIL.

    Evidence dCLIP in mouse and human cells, motif analysis, in vitro binding with motif mutants, antisense oligonucleotide intervention

    PMID:29073373

    Open questions at the time
    • Functional consequence of 3' UTR binding on each transcript unclear
    • Link between cytoplasmic RNA binding and chromatin role unresolved
  16. 2017 Medium

    Linked CBX7 to KRAS control via positive regulation of miR-155, illustrating an indirect post-transcriptional output.

    Evidence miRNA microarray in Cbx7-null vs WT MEFs, miR-155 transfection with KRAS Western blot, colon carcinoma tissue correlation

    PMID:28259135

    Open questions at the time
    • Mechanism of miR-155 promoter regulation by CBX7 not shown
    • Single lab
  17. 2018 Medium

    Positioned CBX7 upstream of a YAP/TAZ–CTGF–JNK axis to restrain glioma migration.

    Evidence Overexpression, GSEA, Western blot for CTGF/p-JNK, genetic rescue (CTGF OE, CA-JNK), migration assays

    PMID:27291091

    Open questions at the time
    • Direct promoter targets in the axis not mapped
    • Single lab
  18. 2019 Medium

    Identified the H3K9 methyltransferases SETDB1, EHMT1 and EHMT2 as CBX7 partners recognized through trimethyl-lysine motifs, extending chromodomain reading to non-histone methylated proteins.

    Evidence Mass spectrometry interactome, Co-IP, SETDB1 knockdown phenocopy in AML cells, HSPC xenotransplant

    PMID:30759399

    Open questions at the time
    • Direct vs bridged interactions not all resolved
    • Single lab
  19. 2019 Medium

    Characterized a positive allosteric modulator (UNC4976) that re-equilibrates PRC1 off H3K27me3 targets by enhancing non-specific nucleic-acid binding, refining the pharmacological model.

    Evidence Quantitative cellular chromodomain assay, ChIP displacement, fluorescence polarization, reporter assays

    PMID:31422906

    Open questions at the time
    • In vivo relevance not tested
    • Single lab
  20. 2020 Medium

    Showed CBX7 directly occludes the E-box to block TWIST-1-driven mesenchymal transformation in ovarian cancer.

    Evidence CRISPR/genetic CBX7 deletion, E-box reporter assays, in vivo tumorigenicity

    PMID:32205869

    Open questions at the time
    • Direct CBX7–DNA contact at the E-box not structurally characterized
    • Single lab
  21. 2020 Medium

    Established that two CBX7 isoforms partition between nucleus and cytoplasm with opposing proliferative functions, indicating isoform-resolved biology.

    Evidence Molecular cloning, subcellular fractionation, immunofluorescence, serum starvation and proliferation assays

    PMID:32415167

    Open questions at the time
    • Molecular basis of cytoplasmic p22CBX7 anti-proliferative effect unknown
    • Single lab
  22. 2021 Medium

    Defined a CBX7/AKR1B10/ERK repressive axis in bladder cancer through PRC1-dependent transcriptional silencing.

    Evidence RNA-seq, ChIP at AKR1B10, siRNA rescue, ERK Western blot, xenografts

    PMID:34035231

    Open questions at the time
    • How AKR1B10 controls ERK not mechanistically resolved
    • Single lab
  23. 2021 Medium

    Identified PDE4B as another directly repressed PRC1-dependent CBX7 target in bladder cancer.

    Evidence ChIP at PDE4B promoter, luciferase reporter, knockdown/overexpression

    PMID:34977026

    Open questions at the time
    • Downstream signaling consequence not detailed here
    • Single lab
  24. 2022 Medium

    Established RNF26 as an E3 ligase driving ubiquitin-dependent CBX7 degradation, defining a route for CBX7 protein turnover in renal cancer.

    Evidence Co-IP, ubiquitination assay, cycloheximide chase, RNF26 KD/OE, xenografts

    PMID:35342353

    Open questions at the time
    • Ubiquitination site on CBX7 not mapped
    • Single lab
  25. 2022 Medium

    Placed CBX7 in an EZH2-repressed feedback loop and showed CBX7 represses FGFR3 to sensitize bladder cancer to cisplatin via PI3K-AKT inactivation.

    Evidence ChIP-qPCR at CBX7 and FGFR3 promoters, RT-qPCR/Western blot, cisplatin sensitivity assay, xenograft

    PMID:36396821

    Open questions at the time
    • Direct vs indirect PI3K-AKT modulation not separated
    • Single lab
  26. 2022 Low

    Linked CBX7 to immune evasion through a CBX7/POU2F2/PD-L1 axis governing PD-1 blockade response.

    Evidence RNA-seq, Western blot/RT-qPCR for POU2F2 and PD-L1, PD-1 blockade functional assay

    PMID:35526483

    Open questions at the time
    • POU2F2 intermediate to PD-L1 not directly demonstrated at the promoter — indirect inference
    • Single lab
  27. 2022 Medium

    Showed circ_0006790 promotes CBX7 nuclear translocation enabling DNMT-mediated S100A11 silencing to suppress pancreatic cancer immune escape.

    Evidence RNA pull-down/RIP, fractionation, ChIP for DNMT at S100A11, siRNA knockdowns, xenografts

    PMID:35693076

    Open questions at the time
    • How circRNA controls CBX7 trafficking mechanistically unclear
    • Single lab
  28. 2023 High

    Defined a CBX7–TARDBP–RBM38 axis driving postnatal cardiomyocyte cell-cycle exit, revealing a developmental, non-canonical CBX7 program.

    Evidence Co-IP/MS for CBX7–TARDBP, cardiac-specific KO mice, adenoviral overexpression, proliferation immunostaining, injury/regeneration models

    PMID:37158107

    Open questions at the time
    • Whether this axis is PRC1-dependent unresolved
    • Direct RBM38 regulation mechanism not fully mapped
  29. 2024 Medium

    Connected CBX7 to metabolic control by showing it represses USP44, destabilizing c-MYC and reducing LDHA-driven glycolysis in meningioma.

    Evidence iTRAQ proteomics, ChIP at USP44, luciferase reporter, c-MYC stability and proteasome inhibitor assays, xenografts

    PMID:37791390

    Open questions at the time
    • Direct USP44–c-MYC deubiquitination step inferred not proven here
    • Single lab
  30. 2024 Low

    Showed CBX7 blocks Twist1 access to the EphA2 promoter to suppress basal-like breast cancer metastasis.

    Evidence ChIP for Twist1 at EphA2 with/without CBX7, dual-luciferase, migration/invasion assays

    PMID:35843065

    Open questions at the time
    • Direct CBX7–Twist1 binding not characterized — competitive mechanism inferred
    • Single lab
  31. 2024 Medium

    Identified RNF2 as a second E3 ligase degrading CBX7 in chondrosarcoma, reinforcing ubiquitin-proteasomal control of CBX7 abundance.

    Evidence Co-IP, ubiquitination assay, cycloheximide chase, RNF2 KD/OE, xenograft

    PMID:39456039

    Open questions at the time
    • Relationship between RNF2 and RNF26 in CBX7 turnover unknown
    • Single lab
  32. 2024 Medium

    Revealed a pro-angiogenic CBX7/HIF-1α/VEGF program under hypoxia, an activating role in vascular endothelial cells.

    Evidence Knockdown/overexpression in HCVECs, Western blot, nuclear fractionation, angiogenesis assays, laser-induced CNV mouse model

    PMID:39179168

    Open questions at the time
    • Direct vs indirect HIF-1α transcriptional control unresolved
    • Single lab
  33. 2024 Medium

    Confirmed CBX7 partnering with EHMT1/2 and SETDB1 and showed CBX7 inhibitors disrupt these interactions, lowering H3K9 methylation and affecting H2Aub-mediated repression.

    Evidence Co-IP, pharmacological CBX7 inhibition, H3K9me and H2Aub Western blot, expression and combination growth assays

    PMID:39613290

    Open questions at the time
    • Whether H3K9-MTase recruitment is direct or PRC1-bridged not resolved
    • Single lab
  34. 2025 Medium

    Placed CBX7 in a DNMT1/CBX7/ERK axis in pancreatic cancer, where promoter methylation silences CBX7 to relieve ERK suppression.

    Evidence ChIP for DNMT1 at CBX7 promoter, dual-luciferase, DNMT1 knockdown with CBX7/ERK readout, functional assays

    PMID:40387566

    Open questions at the time
    • How CBX7 restrains ERK mechanistically not defined
    • Single lab
  35. 2026 Medium

    Uncovered a lymphoid-specific, non-canonical CBX7: a cytosolic c-Raf/MEK1/2/CK2-α signaling scaffold sustaining ERK1/2 and a methylation-dependent transcriptional activator of cytokine genes.

    Evidence Co-IP, ChIP at cytokine promoters, fractionation, genetic KO and pharmacological inhibition in mouse/human lymphoid cells, RNA-seq, asthma models

    PMID:41686891

    Open questions at the time
    • Molecular basis of cell-type specificity unknown
    • How a Polycomb reader scaffolds cytosolic kinases not structurally defined
  36. 2026 Medium

    Showed CBX7 preferentially reads Ser31-phosphorylated H3.3K27me3 and recruits KAP1 to build H3K9me3 heterochromatin, controlling retrotransposon silencing and X-inactivation.

    Evidence Nucleosome pulldown with defined modifications, H3K9me3 ChIP after disruption, retrotransposon and X-inactivation assays

    PMID:41582043

    Open questions at the time
    • Structural basis of S31ph-K27me3 preference not solved
    • Direct CBX7–KAP1 contact surface unmapped

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CBX7 chooses between its repressor, activator, and cytosolic-scaffold modes — and how RNA, DNA, and methyl-lysine reading are integrated to determine context-specific output — remains unresolved.
  • No unifying model linking nuclear/cytoplasmic isoforms, lymphoid scaffold function, and PRC1 repression
  • Determinants of activator vs repressor outcome at individual promoters undefined
  • Integration of 3' UTR mRNA binding with chromatin role unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 4 GO:0140110 transcription regulator activity 4 GO:0042393 histone binding 3 GO:0003677 DNA binding 2 GO:0003723 RNA binding 2
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 2 GO:0000228 nuclear chromosome 1
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-162582 Signal Transduction 3 R-HSA-1640170 Cell Cycle 3 R-HSA-1643685 Disease 3 R-HSA-4839726 Chromatin organization 3
Partners
EHMT1HDAC2KAP1RING1RNF2SETDB1SUV39H2TARDBP
Complex memberships
PRC1

Evidence

Reading pass · 36 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 CBX7 interacts with Ring1 and localizes to nuclear Polycomb bodies, functioning as a PRC1 component to repress the Ink4a/Arf locus and extend cellular lifespan; shRNA ablation of CBX7 induced growth arrest via induction of Ink4a/Arf. Co-immunoprecipitation (Ring1 interaction), immunofluorescence (nuclear Polycomb body localization), shRNA knockdown with p16/Arf induction readout, cDNA screen for senescence bypass Nature cell biology High 14647293
2010 CBX7 within PRC1 binds directly to the noncoding RNA ANRIL via its chromodomain; in concert with H3K27me3 recognition, RNA binding is required for CBX7-mediated repression of the INK4b/ARF/INK4a locus. Structure-guided analysis revealed the molecular interplay between noncoding RNA and H3K27me3 as mediated by the conserved chromodomain. RNA immunoprecipitation, NMR structural analysis of chromodomain–RNA interaction, chromodomain mutants disrupting RNA or H3K27me binding, ChIP at INK4a/ARF locus, senescence assays Molecular cell High 20541999
2005 CBX7 represses p16INK4a and p14ARF expression in normal and tumor-derived prostate cells; shRNA knockdown upregulates both p16 and p14ARF and impairs cell growth in a manner dependent on the p16/Rb and p14ARF/p53 pathway status. shRNA knockdown, Western blot for p16/p14ARF, growth assays in LNCaP and PC-3 cells Oncogene Medium 15897876
2007 CBX7 represses the Ink4a/Arf locus and acts epistatically to the Arf-p53 pathway during lymphomagenesis in vivo; transgenic targeting of Cbx7 to the lymphoid compartment initiated T cell lymphomagenesis and cooperated with c-Myc to produce B cell lymphomas. Transgenic mouse model (lymphoid-targeted Cbx7 expression), genetic epistasis with Arf-p53 pathway, tumor characterization Proceedings of the National Academy of Sciences of the United States of America High 17374722
2009 CBX7 (PRC1 component) physically associates with DNA methyltransferase (DNMT) enzymes; CBX7 can initiate stable repression and promoter DNA hypermethylation of cancer-silenced genes in embryonal carcinoma cells, and DNMTs are assembled at CBX7 target gene promoters. Co-immunoprecipitation (CBX7–DNMT interaction), ChIP (DNMT assembly at CBX7 target promoters), CBX7 knockdown/sustained expression in EC cells, epigenomic analysis Cancer research Medium 19602592
2010 CBX7 recruits the H3K9 methyltransferase SUV39H2 to the p16 promoter, initiating H3K9me3 formation; chromodomain mutations or Pc-box deletion abolished CBX7 binding and H3K9me3 formation; CBX7–SUV39H2 complexes were detected in the nucleus by bimolecular fluorescence complementation. ChIP (CBX7, SUV39H2, H3K9me3 at p16 locus), BiFC (CBX7–SUV39H2 nuclear complex), chromodomain/Pc-box mutants, siRNA knockdown of Suv39h2 PloS one Medium 21060834
2012 CBX7 is necessary for recruitment of Ring1B to chromatin in ESCs; Cbx7-containing PRC1 complexes primarily control early-lineage commitment whereas RYBP-containing PRC1 complexes regulate metabolism and cell-cycle progression. Cbx7 is the primary Polycomb ortholog of PRC1 in ESCs and directly represses Cbx2, Cbx4, and Cbx8. ChIP-seq (genomic localization), Cbx7 knockdown (Ring1B chromatin recruitment), reporter assays, ESC differentiation assays Cell reports High 22226354 23273917
2012 Cbx7 knockout mice develop liver and lung adenomas and carcinomas; Cbx7 null MEFs show increased proliferation and reduced senescence; CBX7 binds the CCNE1 (cyclin E) promoter in a complex containing HDAC2 and negatively regulates CCNE1 expression. Cbx7 knockout mouse generation, ChIP (CBX7 and HDAC2 at CCNE1 promoter), Western blot, MEF proliferation/senescence assays, human tumor tissue correlation The Journal of clinical investigation High 22214847
2013 MAPK signaling phosphorylates Cbx7 at Thr-118 (near the Polycomb box); a site-specific antibody confirms this phosphorylation in mammary carcinoma cells blocked by MEK inhibitors; upon EGF stimulation, phosphorylated Cbx7 interacts more robustly with other PRC1 members; Thr-118 phosphorylation moderately enhances repression of the p16 target gene in RAS-induced senescence. Mass spectrometry identification of phosphorylation site, site-specific antibody generation, MEK inhibitor treatment, EGF stimulation + Co-IP with PRC1 members, p16 repression assay with phosphomimetic mutant The Journal of biological chemistry Medium 24194518
2014 CBX7 inhibits Wnt/β-catenin signaling in breast epithelial cells by enhancing transcription of DKK-1 (a Wnt antagonist) through cooperation with p300 acetyltransferase and increased histone acetylation at the DKK-1 promoter; DKK-1 pharmacological inhibition in CBX7-overexpressing cells rescues Wnt signaling and the CD44+/CD24-/ESA+ stem-like cell population. ChIP (CBX7 and p300 at DKK-1 promoter, histone acetylation), shRNA knockdown and overexpression, pharmacological DKK-1 inhibition, stem-cell population assays FASEB journal Medium 25351982
2014 CBX7 negatively or positively regulates several cancer-relevant genes (e.g., SPP1/osteopontin repressed; FOS/FOSB/EGR1 activated) by interacting with their promoter regions and modulating transcriptional activity, as shown by ChIP and gene expression profiling after CBX7 restoration. Gene expression profiling after CBX7 restoration, ChIP at gene promoters, qRT-PCR correlation in human thyroid and lung carcinoma tissues PloS one Medium 24865347
2015 Crystal structures of CBX7 chromodomain with small-molecule inhibitors reveal the binding modes; inhibitors compete with H3K27me3 peptide binding through interactions with key residues in the methyl-lysine binding aromatic cage; lead compound MS37452 displaces CBX7 from the INK4A/ARF locus and derepresses p16/CDKN2A transcription in prostate cancer cells. X-ray crystallography of CBX7ChD–inhibitor complexes, fluorescence polarization binding assays, ChIP (CBX7 displacement from INK4A/ARF locus), gene expression assays in PC3 cells Chemistry & biology High 25660273
2016 By live-cell single-molecule tracking, Cbx7 requires co-recognition of both H3K27me3 and DNA for chromatin targeting; the chromodomain (CD) and AT-hook-like (ATL) motif constitute a functional DNA-binding unit; H3K27me3 contributes significantly to Cbx7 and Cbx8 chromatin targeting but less to Cbx2, Cbx4, Cbx6; disruption of PRC1 complex formation facilitates Cbx7 chromatin targeting. Live-cell single-molecule tracking (SMT), CRISPR genetic engineering of H3K27me3 pathway, biochemical DNA-binding assays, Cbx7 CD and ATL mutants eLife High 27723458
2016 Structure-guided discovery of Class B antagonist MS351, which inhibits H3K27me3 binding when CBX7ChD is bound to RNA; crystal structure of CBX7ChD/MS351 reveals ligand recognition by aromatic cage residues; MS351 induces derepression of CBX7 target genes including p16 in mESCs and PC3 cells. X-ray crystallography of CBX7ChD/MS351 complex, fluorescence polarization assays, gene expression assays (p16 derepression in mESC and PC3) ACS medicinal chemistry letters High 27326334
2017 dCLIP reveals that CBX7 predominantly binds 3' UTRs of mRNAs with a median footprint of ~171–183 nucleotides; four families of consensus RNA motifs were identified and their mutation abolishes CBX7 binding in vitro; antisense oligonucleotide intervention paradoxically increases CBX7 binding and enhances gene expression. Denaturing CLIP (dCLIP) in mouse and human cells, bioinformatic motif analysis, in vitro RNA binding with motif-mutant constructs, antisense oligonucleotide pharmacological intervention Cell systems High 29073373
2017 CBX7 positively regulates miR-155 expression in MEFs and colon carcinomas, and miR-155 in turn targets KRAS protein levels; Cbx7-null MEFs show downregulation of miR-155 and corresponding upregulation of KRAS protein. miRNA microarray of Cbx7-null vs. WT MEFs, qRT-PCR validation, miR-155 transfection with Western blot for KRAS, human colon carcinoma tissue correlation BMC cancer Medium 28259135
2018 CBX7 represses YAP/TAZ-dependent transcription in glioblastoma; CBX7 overexpression represses CTGF (a YAP/TAZ target) and reduces phospho-JNK; CBX7 fails to inhibit glioma cell migration when CTGF is exogenously overexpressed or constitutively active JNK is present, placing CBX7 upstream of the YAP/TAZ-CTGF-JNK axis. Exogenous CBX7 overexpression, GSEA of CBX7-regulated genes identifying YAP/TAZ targets, Western blot (CTGF, p-JNK), genetic rescue experiments (CTGF OE, CA-JNK), migration assays Scientific reports Medium 27291091
2019 CBX7 interacts with non-histone proteins bearing trimethylated lysine peptide motifs similar to H3K27me3: the H3K9 methyltransferases SETDB1, EHMT1, and EHMT2 were identified as CBX7-binding proteins by mass spectrometry; depletion of SETDB1 in AML cells phenocopied CBX7 repression. Mass spectrometry of CBX7-associated proteins, Co-IP validation, SETDB1 knockdown phenocopy assay in AML cells, xenotransplantation of CBX7-overexpressing HSPCs Cell reports Medium 30759399
2019 A positive allosteric modulator (PAM) peptidomimetic UNC4976 simultaneously antagonizes H3K27me3-specific recruitment of CBX7 to target genes while increasing non-specific DNA/RNA binding, re-equilibrating PRC1 away from H3K27me3 target regions; this was demonstrated across three orthogonal cellular assays. Quantitative cellular CBX7 chromodomain assay, ChIP (target gene displacement), fluorescence polarization, cellular reporter assays Cell chemical biology Medium 31422906
2020 CBX7 binds directly to the E-box element to preclude TWIST-1 from binding its E-box in secondary ovarian cancer cells; deletion of CBX7 reactivates TWIST-1-induced transcription and promotes mesenchymal transformation and enhanced tumorigenicity in vivo. CBX7 deletion (CRISPR/genetic), reporter assays for TWIST-1 transcriptional activity at E-box, in vivo tumorigenicity assays Oncogene Medium 32205869
2020 The two CBX7 isoforms p36CBX7 and p22CBX7 exhibit distinct subcellular localization and opposing proliferative functions: p36CBX7 localizes to the nucleus and is expressed in proliferating cells, while p22CBX7 localizes to the cytoplasm, is induced by serum starvation, and inhibits cell proliferation. Isoform identification by molecular cloning, subcellular fractionation, immunofluorescence, serum starvation experiments, proliferation assays Scientific reports Medium 32415167
2021 CBX7 transcriptionally suppresses AKR1B10 in a PRC1-dependent manner (identified by RNA-seq and ChIP); AKR1B10 downregulation by CBX7 inactivates ERK signaling, establishing a CBX7/AKR1B10/ERK signaling axis in urinary bladder cancer. RNA-seq after CBX7 manipulation, ChIP assay at AKR1B10 locus, siRNA knockdown of AKR1B10, ERK signaling Western blot, xenograft tumor models Cell death & disease Medium 34035231
2021 CBX7 transcriptionally suppresses PDE4B at the transcription level in a PRC1-dependent manner in bladder cancer cells, as demonstrated by ChIP and luciferase assays. ChIP (CBX7 at PDE4B promoter), luciferase reporter assay, CBX7 knockdown/overexpression with PDE4B expression readout Frontiers in cell and developmental biology Medium 34977026
2022 RNF26 promotes ubiquitin-mediated proteasomal degradation of CBX7 in clear cell renal cell carcinoma; RNF26 knockdown reduces CBX7 ubiquitination, stabilizes CBX7 protein, and inhibits tumor growth, establishing RNF26 as a CBX7 E3 ubiquitin ligase. Co-IP (RNF26–CBX7 interaction), ubiquitination assay, cycloheximide chase (protein stability), RNF26 KD/OE with CBX7 protein level readout, xenograft models International journal of biological sciences Medium 35342353
2022 EZH2 represses CBX7 expression by increasing H3K27me3 at the CBX7 promoter in bladder cancer cells; CBX7 in turn directly downregulates FGFR3 expression (shown by ChIP-qPCR) and sensitizes bladder cancer cells to cisplatin by inactivating PI3K-AKT signaling. ChIP-qPCR (H3K27me3 at CBX7 promoter; CBX7 at FGFR3 promoter), RT-qPCR, Western blot, CCK-8 cisplatin sensitivity assay, xenograft mouse model British journal of cancer Medium 36396821
2022 CBX7 downregulates POU2F2 expression, which indirectly represses PD-L1 in bladder cancer cells; depletion of CBX7 results in resistance to PD-1 blockade, establishing a CBX7/POU2F2/PD-L1 regulatory axis. RNA-seq (CBX7 KD, GSE185630), Western blot/RT-qPCR (POU2F2, PD-L1), PD-1 blockade functional assay Biochemical and biophysical research communications Low 35526483
2022 Circ_0006790 facilitates nuclear translocation of CBX7; nuclear CBX7 increases DNA methylation of S100A11 by recruiting DNA methyltransferases to its promoter, thereby inhibiting S100A11 transcription and suppressing PDAC immune escape. RNA pull-down and RIP (circ_6790–CBX7 interaction), subcellular fractionation (CBX7 nuclear translocation), ChIP (DNMT recruitment to S100A11 promoter), siRNA knockdowns, xenograft assays American journal of cancer research Medium 35693076
2023 CBX7 interacts with TARDBP (TDP-43) and positively regulates its downstream target RBM38 in a TARDBP-dependent manner; this CBX7–TARDBP–RBM38 axis drives cardiomyocyte cell cycle exit postnatally, and Cbx7 genetic inactivation promotes cardiomyocyte proliferation and cardiac regeneration after injury. Co-immunoprecipitation + mass spectrometry (CBX7–TARDBP interaction), conditional and inducible cardiac-specific KO mice, adenoviral CBX7 overexpression, immunostaining for proliferation markers, neonatal apical resection and adult MI models Circulation High 37158107
2024 CBX7 transcriptionally inhibits USP44 expression; reduced USP44 promotes proteasome-dependent degradation of c-MYC protein, consequently attenuating c-MYC-mediated transactivation of LDHA and inhibiting glycolysis in meningioma cells. iTRAQ proteomics after CBX7 restoration, ChIP (CBX7 at USP44 promoter), luciferase reporter assay, Western blot (c-MYC stability), proteasome inhibitor experiments, xenograft mouse models Journal of molecular cell biology Medium 37791390
2024 CBX7 blocks Twist1 binding to the EphA2 promoter and inhibits EphA2 expression; loss of CBX7 allows Twist1 to transactivate EphA2, promoting BLBC metastasis via the Twist1/EphA2 axis. ChIP assay (Twist1 at EphA2 promoter with/without CBX7), dual-luciferase reporter assay, Western blot, in vitro migration/invasion assays Translational oncology Low 35843065
2024 RNF2 promotes ubiquitination and proteasomal degradation of CBX7 in chondrosarcoma; RNF2 knockdown reduces CBX7 ubiquitination and increases CBX7 protein stability (cycloheximide chase), without affecting CBX7 mRNA levels. Co-IP, ubiquitination assay, cycloheximide chase (protein stability), RNF2 KD/OE with CBX7 readout, xenograft mouse model Cancer & metabolism Medium 39456039
2024 CBX7 promotes HIF-1α transcription and nuclear translocation and transcriptional activity in choroidal vascular endothelial cells under hypoxia, which in turn stimulates VEGF transcription and promotes pro-angiogenic behaviors (migration, proliferation, tube formation) via the CBX7/HIF-1α/VEGF pathway. CBX7 knockdown/overexpression in HCVECs, Western blot (HIF-1α, VEGF), nuclear fractionation (HIF-1α translocation), functional angiogenesis assays (migration, tube formation), laser-induced CNV mouse model Experimental eye research Medium 39179168
2024 CBX7 interacts with H3K9 methyltransferases EHMT1/2 and SETDB1; pharmacological inhibition of CBX7 abolishes this interaction, reduces H3K9 methylation, and reactivates target gene expression; CBX7 inhibitors also affect H2Aub-mediated (Polycomb) gene repression. Co-IP (CBX7–EHMT1/2/SETDB1), pharmacological CBX7 inhibitor treatment, H3K9me and H2Aub Western blot, gene expression assays, combination drug growth assays Experimental hematology Medium 39613290
2025 DNMT1 methylates the CBX7 promoter region to repress CBX7 expression in PDAC; reduced CBX7 leads to increased ERK phosphorylation, promoting tumorigenesis and metastasis; the DNMT1/CBX7/ERK axis was confirmed by ChIP and dual-luciferase assays. ChIP (DNMT1 at CBX7 promoter), dual-luciferase reporter assay, DNMT1 knockdown with CBX7 and ERK readout, CCK-8/wound healing/transwell functional assays FASEB journal Medium 40387566
2026 CBX7 forms a methylation-dependent transcriptional activation complex at cytokine gene promoters in lymphoid cells (unexpected activating role); CBX7 also translocates to the cytosol and forms a methylation-dependent signaling complex with c-Raf, MEK1/2, and CK2-α to sustain ERK1/2 signaling; these activities are lymphoid-cell specific and absent in epithelial cells. Co-IP (CBX7–c-Raf–MEK1/2–CK2α), ChIP (CBX7 at cytokine gene promoters), subcellular fractionation, genetic KO and pharmacological inhibition in mouse and human lymphoid cells, RNA-seq, allergic asthma mouse models Science advances Medium 41686891
2026 CBX7 preferentially binds Ser31-phosphorylated H3.3K27me3 nucleosomes and recruits KAP1 (KRAB-associated protein 1); disruption of the H3.3–CBX7 interaction impairs H3K9me3 heterochromatin formation and activates retrotransposons; during X-chromosome inactivation, H3K9me2/3 fails to accumulate at the inactive X when the H3.3–CBX7–KAP1 axis is blocked. Co-IP/nucleosome pulldown (CBX7 binding to H3.3S31ph-K27me3), H3K9me3 ChIP after H3.3–CBX7 disruption, retrotransposon activation assays, X-chromosome inactivation assays Science bulletin Medium 41582043

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Molecular cell 1131 20541999
2003 Polycomb CBX7 has a unifying role in cellular lifespan. Nature cell biology 265 14647293
2012 MicroRNA regulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation. Cell stem cell 170 22226354
2012 RYBP and Cbx7 define specific biological functions of polycomb complexes in mouse embryonic stem cells. Cell reports 169 23273917
2007 Role of the chromobox protein CBX7 in lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America 142 17374722
2012 CBX7 is a tumor suppressor in mice and humans. The Journal of clinical investigation 126 22214847
2005 CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 122 15897876
2015 Small-molecule modulators of methyl-lysine binding for the CBX7 chromodomain. Chemistry & biology 100 25660273
2016 Live-cell single-molecule tracking reveals co-recognition of H3K27me3 and DNA targets polycomb Cbx7-PRC1 to chromatin. eLife 97 27723458
2018 CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-κB-miR-21 pathways. Journal of hematology & oncology 94 29422082
2014 Chromodomain antagonists that target the polycomb-group methyllysine reader protein chromobox homolog 7 (CBX7). Journal of medicinal chemistry 80 24625057
2010 Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. Genes & cancer 69 21779448
2014 CBX7 inhibits breast tumorigenicity through DKK-1-mediated suppression of the Wnt/β-catenin pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 63 25351982
2009 Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer research 62 19602592
2016 Structure-Guided Discovery of Selective Antagonists for the Chromodomain of Polycomb Repressive Protein CBX7. ACS medicinal chemistry letters 56 27326334
2010 Oncogenic role of the chromobox protein CBX7 in gastric cancer. Journal of experimental & clinical cancer research : CR 56 20723236
2015 Polycomb protein family member CBX7 plays a critical role in cancer progression. American journal of cancer research 53 26175930
2019 Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7. Cell chemical biology 50 31422906
2021 CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling. Cell death & disease 45 34035231
2018 Robustness of In Vitro Selection Assays of DNA-Encoded Peptidomimetic Ligands to CBX7 and CBX8. SLAS discovery : advancing life sciences R & D 44 29309209
2017 CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer. Oncotarget 43 28030829
2010 Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus. PloS one 42 21060834
2021 Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer. Molecular oncology 36 33400401
2018 miRNA-19 promotes non-small-cell lung cancer cell proliferation via inhibiting CBX7 expression. OncoTargets and therapy 36 30584339
2016 Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget 36 27449098
2020 CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential. Oncogene 34 32205869
2019 CBX7 Induces Self-Renewal of Human Normal and Malignant Hematopoietic Stem and Progenitor Cells by Canonical and Non-canonical Interactions. Cell reports 33 30759399
2017 CBX7 negatively regulates migration and invasion in glioma via Wnt/β-catenin pathway inactivation. Oncotarget 33 28388562
2016 Cbx7 is epigenetically silenced in glioblastoma and inhibits cell migration by targeting YAP/TAZ-dependent transcription. Scientific reports 33 27291091
2015 Up-regulation of miR-9 target CBX7 to regulate invasion ability of bladder transitional cell carcinoma. Medical science monitor : international medical journal of experimental and clinical research 32 25596753
2012 Tumor suppressor activity of CBX7 in lung carcinogenesis. Cell cycle (Georgetown, Tex.) 30 22544325
2020 The Crosstalk between lncRNA-SNHG7/miRNA-181/cbx7 Modulates Malignant Character in Lung Adenocarcinoma. The American journal of pathology 29 32201260
2014 CBX7 modulates the expression of genes critical for cancer progression. PloS one 29 24865347
2019 CBX7 Inhibits Cell Growth and Motility and Induces Apoptosis in Cervical Cancer Cells. Molecular therapy oncolytics 28 31709304
2013 Synthetic trimethyllysine receptors that bind histone 3, trimethyllysine 27 (H3K27me3) and disrupt its interaction with the epigenetic reader protein CBX7. Bioorganic & medicinal chemistry 28 24100156
2022 Circ_0006790 carried by bone marrow mesenchymal stem cell-derived exosomes regulates S100A11 DNA methylation through binding to CBX7 in pancreatic ductal adenocarcinoma. American journal of cancer research 24 35693076
2015 Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment. Naunyn-Schmiedeberg's archives of pharmacology 24 26216446
2017 miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. BMC cancer 23 28259135
2022 The RNF26/CBX7 axis modulates the TNF pathway to promote cell proliferation and regulate sensitivity to TKIs in ccRCC. International journal of biological sciences 22 35342353
2017 The malignancy of miR-18a in human glioblastoma via directly targeting CBX7. American journal of cancer research 22 28123848
2017 Denaturing CLIP, dCLIP, Pipeline Identifies Discrete RNA Footprints on Chromatin-Associated Proteins and Reveals that CBX7 Targets 3' UTRs to Regulate mRNA Expression. Cell systems 22 29073373
2020 CBX7 suppression prevents ischemia-reperfusion injury-induced endoplasmic reticulum stress through the Nrf-2/HO-1 pathway. American journal of physiology. Renal physiology 20 32390514
2015 CBX7 and miR-9 are part of an autoregulatory loop controlling p16(INK) (4a). Aging cell 20 26416703
2021 PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7. Frontiers in cell and developmental biology 19 34977026
2018 [ARTICLE WITHDRAWN] MicroRNA-18a Targets IRF2 and CBX7 to Promote Cell Proliferation in Hepatocellular Carcinoma. Oncology research 19 29386090
2023 Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis. Circulation 18 37158107
2021 CBX7 is Dualistic in Cancer Progression Based on its Function and Molecular Interactions. Frontiers in genetics 17 34659360
2019 Single Nucleotide Polymorphisms of CBX4 and CBX7 Decrease the Risk of Hepatocellular Carcinoma. BioMed research international 17 31211140
2018 Potential role of CBX7 in regulating pluripotency of adult human pluripotent-like olfactory stem cells in stroke model. Cell death & disease 17 29717132
2015 Critical evaluation of Cbx7 downregulation in primary colon carcinomas and its clinical significance in Chinese patients. BMC cancer 17 25881303
2018 Polycomb protein family member CBX7 regulates intrinsic axon growth and regeneration. Cell death and differentiation 16 29459770
2020 lncRNA NEAT1 Facilitates Cell Proliferation, Invasion and Migration by Regulating CBX7 and RTCB in Breast Cancer. OncoTargets and therapy 15 32273717
2020 Resveratrol inhibits oral squamous cell carcinoma cells proliferation while promoting apoptosis through inhibition of CBX7 protein. Environmental toxicology 15 32621571
2014 Tracing dynamics and clonal heterogeneity of Cbx7-induced leukemic stem cells by cellular barcoding. Stem cell reports 15 25434821
2016 Structure-Activity Relationships of Cbx7 Inhibitors, Including Selectivity Studies against Other Cbx Proteins. ACS omega 14 30023485
2023 Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells. Journal of ovarian research 13 38037081
2022 Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7. Cellular and molecular life sciences : CMLS 13 35867177
2022 Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer. British journal of cancer 13 36396821
2020 Regulation of circGOLPH3 and its binding protein CBX7 on the proliferation and apoptosis of prostate cancer cells. Bioscience reports 13 33245100
2016 CBX7 deficiency plays a positive role in dentin and alveolar bone development. Journal of molecular histology 12 27271093
2024 IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma. Cell death discovery 11 38413558
2022 Knockdown of CBX7 inhibits ferroptosis in rats with cerebral ischemia and improves cognitive dysfunction by activating the Nrf2/HO-1 pathway. Journal of biosciences 11 36222130
2013 Mitogen-activated protein kinase signaling mediates phosphorylation of polycomb ortholog Cbx7. The Journal of biological chemistry 11 24194518
2022 CBX7 regulates metastasis of basal-like breast cancer through Twist1/EphA2 pathway. Translational oncology 10 35843065
2020 MicroRNA-18a suppresses ovarian carcinoma progression by targeting CBX7 and regulating ERK/MAPK signaling pathway and epithelial-to-mesenchymal transition. European review for medical and pharmacological sciences 10 32495862
2019 Mechanisms of ischaemic neural progenitor proliferation: a regulatory role of the HIF-1α-CBX7 pathway. Neuropathology and applied neurobiology 10 31630421
2008 [MiR-9 regulates the expression of CBX7 in human glioma]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 10 18686603
2023 LncRNA RNA ROR Aggravates Hypoxia/Reoxygenation-Induced Cardiomyocyte Ferroptosis by Targeting miR-769-5p/CBX7 Axis. Biochemical genetics 9 38157079
2020 Mammalian CBX7 isoforms p36 and p22 exhibit differential responses to serum, varying functions for proliferation, and distinct subcellular localization. Scientific reports 9 32415167
2018 Effect of CBX7 deficiency on the socket healing after tooth extractions. Journal of bone and mineral metabolism 8 30238429
2024 CBX7 promotes choroidal neovascularization by activating the HIF-1α/VEGF pathway in choroidal vascular endothelial cells. Experimental eye research 7 39179168
2021 Expression and correlation analysis of Skp2 and CBX7 in cervical cancer. Journal of clinical pathology 7 34281957
2019 Rational Adaptation of L3MBTL1 Inhibitors to Create Small-Molecule Cbx7 Antagonists. ChemMedChem 7 31254321
2024 CBX7 reprograms metabolic flux to protect against meningioma progression by modulating the USP44/c-MYC/LDHA axis. Journal of molecular cell biology 6 37791390
2024 RNF2 promotes chondrosarcoma progression by regulating ubiquitination and degradation of CBX7. Cancer & metabolism 6 39456039
2018 The molecular selectivity of UNC3866 inhibitor for Polycomb CBX7 protein from molecular dynamics simulation. Computational biology and chemistry 6 29723807
2017 Producing GST-Cbx7 Fusion Proteins from Escherichia coli. Bio-protocol 6 28966944
2014 CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas). European thyroid journal 6 25759796
2024 CBX7 silencing promoted liver regeneration by interacting with BMI1 and activating the Nrf2/ARE signaling pathway. Scientific reports 5 38744845
2023 Subcellular expression pattern and clinical significance of CBX2 and CBX7 in breast cancer subtypes. Medical molecular morphology 5 37553450
2022 CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer. Biochemical and biophysical research communications 5 35526483
2017 Aza-amino acid scanning of chromobox homolog 7 (CBX7) ligands. Journal of peptide science : an official publication of the European Peptide Society 5 28220557
2023 CBX7 Rejuvenates Late Passage Dental Pulp Stem Cells by Maintaining Stemness and Pro-angiogenic Ability. Tissue engineering and regenerative medicine 4 36920677
2023 Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy. Medical oncology (Northwood, London, England) 4 38112798
2024 Targeting the Ferroptosis and Endoplasmic Reticulum Stress Signaling Pathways by CBX7 in Myocardial Ischemia/reperfusion Injury. Cell biochemistry and biophysics 3 38809351
2023 Cbx7 promotes the generation of induced pluripotent stem cells. Regenerative therapy 3 37753387
2024 A novel nanoplatform-based circCSNK1G3 affects CBX7 protein and promotes glioma cell growth. International journal of biological macromolecules 2 39033888
2024 CBX7 inhibitors affect H3K9 methyltransferase-regulated gene repression in leukemic cells. Experimental hematology 2 39613290
2023 CBX7 is involved in the progression of cervical cancer through the ITGβ3/TGFβ1/AKT pathway. Oncology letters 2 38028179
2022 The expression of miR-181b, CYLD, CBX-7, BCL2, and p53 in osteosarcoma patients and correlation with clinicopathological factors. Chemical biology & drug design 2 36098711
2020 lncRNA NEAT1 Facilitates Cell Proliferation, Invasion and Migration by Regulating CBX7 and RTCB in Breast Cancer [Retraction]. OncoTargets and therapy 2 32848416
2025 Chromobox protein homolog 7 (CBX7) deficiency inhibits osteoblast ferroptosis by activating the Nrf2 function in type 2 diabetic osteoporosis. The international journal of biochemistry & cell biology 1 40998236
2025 Engineered Multifunctional Hydrogel Delivering Novel CBX7 Inhibitor Modulates Cuproptosis Via Liquid-Liquid Phase Separation to Restore Cardiac Function in Aged Myocardial Infarction. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 1 41117088
2025 CBX7 regulates chemotherapy-induced senescence-like growth arrest in multiple myeloma via the ERK/STAT3/PIM1 axis. Journal of translational medicine 1 41250171
2026 Histone H3.3 phosphorylation facilitates H3K9me3-heterochromatin formation during retrotransposon silencing and X-chromosome inactivation via H3.3K27me3-CBX7-KAP1 axis. Science bulletin 0 41582043
2026 CBX7 functions as a methylation-dependent inducer of gene transcription and regulator of cytosolic signaling in lymphoid cells. Science advances 0 41686891
2025 DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progression. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 0 40387566
2024 Study on the Role of EPHB6 in Inhibiting the Malignant Progression of Cervical Cancer C33A Cells by Binding to CBX7. Cell biochemistry and biophysics 0 39322790
2024 Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells. Blood neoplasia 0 40552137
2023 Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells. bioRxiv : the preprint server for biology 0 37986971

Missed literature

Know a paper Affinage missed for CBX7? Flag it for the maintainers and the community.

No submissions yet.